title: High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment.
authors.forename: Jean
authors.initials: J
authors.lastname: Szymezak
authors.forename: Caroline
authors.initials: C
authors.lastname: Moreau
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Loriot
authors.forename: Eric
authors.initials: E
authors.lastname: Durand
authors.forename: Hubert
authors.initials: H
authors.lastname: Van Viet
authors.forename: Michel
authors.initials: M
authors.lastname: Desnos
authors.forename: Pascale
authors.initials: P
authors.lastname: Gaussem
mesh_terms: D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D010979:Platelet Function Tests; D011110:Polymorphism, Genetic; D058925:Receptors, Purinergic P2Y12 / Q000235:genetics; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12; D000077144:Clopidogrel; D013988:Ticlopidine